Literature DB >> 7768763

Improved method of determining the susceptibility of Candida albicans to fluconazole.

A M Polanco1, J L Rodriguez-Tudela, F Baquero, A Sanchez-Sousa, J V Martinez-Suarez.   

Abstract

The MICs of fluconazole for four reference strains of Candida albicans were determined in one laboratory by the macrobroth dilution method recommended by the National Committee for Clinical Laboratory Standards (NCCLS) and by a modified version of the method which incorporated microbroth dilution, RPMI 1640 medium supplemented with glucose and the reading of MIC endpoints by spectrophotometry. The results obtained by the two methods were within one two-fold dilution. In addition, the susceptibilities of 58 clinical isolates of C. albicans to fluconazole were determined in two laboratories by the modified NCCLS method. Close interlaboratory agreement was observed, 98.2% of MICs varying by no more than one two-fold dilution.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7768763     DOI： 10.1093/jac/35.1.155

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  9 in total

1.  International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 2.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

3.  Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis.

Authors:  J Fortún; A López-San Román; J J Velasco; A Sánchez-Sousa; E de Vicente; J Nuño; C Quereda; R Bárcena; G Monge; A Candela; A Honrubia; A Guerrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans.

Authors:  J L Rodríguez-Tudela; J Berenguer; J V Martínez-Suárez; R Sanchez
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Fluconazole Global Susceptibility Study Group.

Authors:  J Bille; M P Glauser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

6.  Fluconazole disk diffusion test with methylene blue- and glucose-enriched Mueller-Hinton agar for determining susceptibility of Candida species.

Authors:  S C Lee; C P Fung; N Lee; L C See; J S Huang; C J Tsai; K S Chen; W B Shieh
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

7.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

8.  Comparison of results obtained by testing with three different agar media and by the NCCLS M27-A method for in vitro testing of fluconazole against Candida spp.

Authors:  M Carmen Rubio; Joaquina Gil; Inmaculada Ramírez De Ocáriz; Rafael Benito; Antonio Rezusta
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

9.  Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.

Authors:  J V Martinez-Suarez; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.